Mirae Asset Global Investments Co. Ltd. Boosts Position in Becton, Dickinson and Company $BDX

Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 16.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 42,572 shares of the medical instruments supplier’s stock after buying an additional 5,933 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Becton, Dickinson and Company were worth $7,968,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in BDX. Brighton Jones LLC boosted its position in shares of Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after buying an additional 877 shares during the period. Empowered Funds LLC lifted its position in Becton, Dickinson and Company by 20.4% during the 1st quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier’s stock worth $1,827,000 after acquiring an additional 1,354 shares in the last quarter. PFG Investments LLC boosted its holdings in Becton, Dickinson and Company by 32.7% in the 2nd quarter. PFG Investments LLC now owns 2,601 shares of the medical instruments supplier’s stock worth $448,000 after acquiring an additional 641 shares during the period. Lecap Asset Management Ltd. acquired a new stake in Becton, Dickinson and Company in the second quarter valued at approximately $284,000. Finally, Hilltop National Bank purchased a new stake in shares of Becton, Dickinson and Company during the second quarter valued at approximately $244,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Insiders Place Their Bets

In related news, Director Bertram L. Scott sold 217 shares of the stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $176.58, for a total transaction of $38,317.86. Following the sale, the director owned 35,816 shares in the company, valued at $6,324,389.28. This represents a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Michael David Garrison sold 1,610 shares of Becton, Dickinson and Company stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $207.46, for a total value of $334,010.60. Following the completion of the transaction, the executive vice president owned 12,095 shares of the company’s stock, valued at approximately $2,509,228.70. The trade was a 11.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 2,680 shares of company stock worth $539,848 over the last three months. 0.40% of the stock is owned by corporate insiders.

Becton, Dickinson and Company Stock Up 1.2%

NYSE:BDX opened at $203.56 on Friday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.64 and a current ratio of 1.11. The company has a market capitalization of $58.00 billion, a price-to-earnings ratio of 34.92, a price-to-earnings-growth ratio of 2.22 and a beta of 0.23. Becton, Dickinson and Company has a one year low of $162.29 and a one year high of $251.99. The stock has a 50-day simple moving average of $198.54 and a 200 day simple moving average of $191.32.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, November 6th. The medical instruments supplier reported $3.96 EPS for the quarter, topping analysts’ consensus estimates of $3.92 by $0.04. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%.The company had revenue of $5.89 billion for the quarter, compared to the consensus estimate of $5.91 billion. During the same quarter last year, the business posted $3.81 EPS. Becton, Dickinson and Company’s quarterly revenue was up 8.3% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. Sell-side analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company declared that its Board of Directors has approved a share buyback program on Tuesday, January 27th that authorizes the company to buyback $10.00 million in shares. This buyback authorization authorizes the medical instruments supplier to repurchase up to 0% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s board of directors believes its shares are undervalued.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 31st. Shareholders of record on Tuesday, March 10th will be paid a dividend of $1.05 per share. The ex-dividend date is Tuesday, March 10th. This represents a $4.20 annualized dividend and a yield of 2.1%. Becton, Dickinson and Company’s payout ratio is presently 72.04%.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. Bank of America raised their price target on shares of Becton, Dickinson and Company from $190.00 to $207.00 and gave the company a “neutral” rating in a report on Monday, January 5th. Royal Bank Of Canada upped their price objective on shares of Becton, Dickinson and Company from $202.00 to $210.00 and gave the company a “sector perform” rating in a research report on Wednesday, December 17th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research report on Wednesday, October 8th. Wall Street Zen downgraded Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Finally, Piper Sandler raised their price objective on Becton, Dickinson and Company from $190.00 to $205.00 and gave the company a “neutral” rating in a research note on Wednesday. Four equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Becton, Dickinson and Company presently has a consensus rating of “Hold” and an average price target of $209.00.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.